Form 4: Aileron Therapeutics Director Acquires Stock Options

Aileron Therapeutics director Reinhard J. Ambros was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.

Summary

• Reinhard J. Ambros, a director at Aileron Therapeutics, was granted 35,000 stock options on December 2, 2024.
• The exercise price of these options is $2.85 per share.
• The options will vest in full on December 2, 2025.
• The options expire on December 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting period of one year is fairly typical for such grants.
• The exercise price of $2.85 is specific to Aileron Therapeutics and its current stock valuation.

Stakeholder Impact

• The granting of stock options to a director can be viewed positively by shareholders as it aligns management's interests with their own.
• The vesting schedule encourages long-term commitment from the director.

Key Dates

Keywords

stock options, director, insider trading, Aileron Therapeutics, ALRN, equity, compensation